Menu Search
Equities

Diagnos Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DGNOF:QBB

Diagnos Inc

Actions
  • Price (USD)0.2175
  • Today's Change0.003 / 1.63%
  • Shares traded300.80k
  • 1 Year change-8.75%
  • Beta-0.1901
Data delayed at least 15 minutes, as of Feb 17 2026 20:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

  • Revenue in CAD (TTM)78.99k
  • Net income in CAD-4.76m
  • Incorporated1996
  • Employees--
  • Location
    Diagnos Inc7005 Taschereau Blvd Suite 340BROSSARD J4Z 1A7CanadaCAN
  • Phone+1 (450) 678-8882
  • Fax+1 (450) 678-8882
  • Websitehttps://www.diagnos.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.